Menu Search
Equities

Towa Pharmaceutical Co Ltd

4553:TYO

Towa Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)3,140.00
  • Today's Change20.00 / 0.64%
  • Shares traded86.90k
  • 1 Year change+15.48%
  • Beta0.6021
Data delayed at least 20 minutes, as of Nov 08 2024 06:30 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 16-Nov-23
  • 15-Aug-24
  • 19-Sep-24
  • 17-Oct-24
  • 07-Nov-24
Select bar for recommendation details.
Recommendations07-Nov-24
Buy2
Outperform2
Hold1
Sell0
Strong Sell0

Share price forecast in JPY

The 4 analysts offering 12 month price targets for Towa Pharmaceutical Co Ltd have a median target of 3,750.00, with a high estimate of 3,880.00 and a low estimate of 3,000.00. The median estimate represents a 19.43% increase from the last price of 3,140.00.
High23.6%3,880.00
Med19.4%3,750.00
Low-4.5%3,000.00

Dividends in JPY

In 2024, Towa Pharmaceutical Co Ltd reported a dividend of 60.00 JPY, equaling last years dividend. The 5 analysts covering the company expect dividends of 60.00 JPY for the upcoming fiscal year, maintaining dividends from this year.
Div growth (TTM)0.00%
More ▼

Earnings history & estimates in JPY

On Aug 08, 2024, Towa Pharmaceutical Co Ltd reported 1st quarter 2025 earnings of 111.64 per share. This result exceeded the 52.30 expectation of the one analyst covering the company and exceeded last year's 1st quarter results by 15.68%.
The next earnings announcement is expected on Nov 14, 2024.
Average growth rate+18.42%
Towa Pharmaceutical Co Ltd reported annual 2024 earnings of 328.59 per share on May 14, 2024.
Average growth rate+139.73%
More ▼

Revenue history & estimates in JPY

Towa Pharmaceutical Co., Ltd. had 1st quarter 2025 revenues of 62.57m. This bettered the 61.50m consensus of the 3 analysts covering the company. This was 14.70% above the prior year's 1st quarter results.
Average growth rate+3.74%
Towa Pharmaceutical Co., Ltd. had revenues for the full year 2024 of 227.93m. This was 9.13% above the prior year's results.
Average growth rate+20.62%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.